The Federal Trade Commission and Boehringer Ingelheim each filed final briefs in D.C. Circuit Court on Monday, with the sides sparring over a cache of documents from a 2008 Aggrenox patent dispute that the drugmaker alleges is protected by attorney-client privilege and the agency claims is not.